Life saving medicine still being denied
Access to Prescribed PCSK9 Inhibitors Remains a Significant Barrier Leaving Patients at Risk for Heart Attacks and Strokes Family Heart Foundation Research Shows Insurance Coverage is an [...]
Lipoprotein (a): Five things you should know
You may have heard about Lipoprotein (a), Lp(a) or often referred to as “Lp little a.” Lp(a) is an independent risk factor for cardiovascular disease.The level of Lp(a) found [...]
Individuals Had More Heart Attacks and Strokes When Cholesterol-lowering Drug Prescription Was Rejected or Unfilled
New research from the Family Heart Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), experienced more [...]
Why are FH patients paying a higher price for PCSK9 inhibitor treatment when a lower price is available, and what can we do about it?
Affordable prescription drugs are necessary so individuals can benefit from advances in medicine to treat conditions such as familial hypercholesterolemia. Medical research and innovation make it possible to actually [...]
Sanofi and Regeneron lower list price for PCSK9 inhibitor
the Family Heart Foundation welcomes Sanofi and Regeneron’s announcement today to lower the list price of its LDL cholesterol lowering treatment, the PCSK9 inhibitor Praluent, to $5,850 annually. This brings the [...]
